{
  "trial_id": "NCT04543253",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "have 50 subjects participate in the intervention arm with MUSE in one year, without modifying other study procedures.",
      "label": "met"
    },
    {
      "criterion": "Patients will be identified by their clinician. Permission will be obtained from the patient in order for one of the investigators to explain the study and obtain informed written consent.",
      "label": "met"
    },
    {
      "criterion": "Baseline history, physical examination, and the necessary baseline tests will be performed based on standard of care and as considered necessary by the treating physician.",
      "label": "met"
    },
    {
      "criterion": "Medical record will be reviewed for demographic information, comorbidities, medical therapy, imaging information and biochemical testing results",
      "label": "met"
    },
    {
      "criterion": "We will use a scoring system to quantify biochemical severity, and to classify clinical abnormalities as mild, moderate and severe (based on existent laboratory and clinical parameters).",
      "label": "met"
    },
    {
      "criterion": "At baseline, all patients will be asked to complete the Cushing QoL questionnaire, SF36 and AddiQol questionnaires.",
      "label": "met"
    },
    {
      "criterion": "Patients will discuss the intervention with MUSE with the study investigator. If they agree to participate in the intervention arm, they will be instructed on its use.",
      "label": "met"
    },
    {
      "criterion": "At follow up, patients will complete AddQoL survey (weekly in the first 3 months, every 4 weeks in the next 6 months, every 3 months in the next 12 months, and then every 6 months until the end of the study) and SF36 survey (every 3 months) until the end of the study.",
      "label": "met"
    },
    {
      "criterion": "For patients in the intervention group, in addition to the above, at the time of enrollment, the study coordinator will help set up the MUSE application on to iPad or iPhone or Android phone.",
      "label": "met"
    },
    {
      "criterion": "The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago.",
      "label": "unknown"
    },
    {
      "criterion": "He came to the clinic for the follow up lab studies after his primary resection surgery.",
      "label": "unknown"
    },
    {
      "criterion": "His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age.",
      "label": "unknown"
    },
    {
      "criterion": "His random GH level is 4 ug/L.",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "systemic supraphysiological GC for any reason within 1 month of enrollment, for more than 2 weeks",
      "label": "does_not_trigger"
    },
    {
      "criterion": "inability to provide informed consent",
      "label": "unknown"
    }
  ],
  "notes": "The patient has a history of Acromegaly and underwent transsphenoidal surgery 4 months ago. He is currently undergoing follow-up lab studies.",
  "_meta": {
    "topic_id": "56",
    "trial_id": "NCT04543253",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}